Appeal No. 1997-0094
Application No. 08/188,232
THE INVENTION
The claimed invention is the compound thymosin " gly-amide, i.e., a peptide
1
consisting of amino acid residues 1-29 of the NH -terminal sequence of prothymosin "
2
wherein the glycine residue at position 29 is amidated.
OPINION
Haritos discloses the NH -terminal sequence of the . 112 amino acid residue
2
polypeptide, prothymosin ", including the sequences for thymosin " and amino acid
1
residues 1-30 for thymosin " (Fig. 6, p. 1011).
11
Abiko I discloses a 30 amino acid residue thymosin " analog having a D-Arg in
11
place of the arginine residue at position 30, which analog has increased resistance to
inactivation by enzyme (exopeptidase) degradation (abstract; p. 752).
Abiko II discloses synthetic deacetyl-thymosin " (Fig. 2, p. 5420) as
11
approximately equal in potency to synthetic deacetyl-thymosin " in increasing E-rosette-
1
forming capacity in cases of rheumatoid arthritis (p. 5419; Fig. 2, p. 5420). Ishimura
discloses four peptides amides derived from thymosin " , i.e., amino acid residue (20-
1
28), (20-27), (20-26) and [Ala-27](20-28) amides (see Figure 2(a), p. 703, peptides 19-
22). According to Ishimura, "the major immunoreactive site of the COOH-terminal half of
thymosin " is segment (21-28), with important contributions by
1
- 5 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007